Snaith headquartered Croda has broken ground on its newest manufacturing facility in Lamar, Pennsylvania.
The company is investing in the new 23,680 square-foot facility to make ingredients for drug delivery systems used in therapeutic drugs such as mRNA vaccines and gene editing therapies. The facility will support the production of lipids already used in therapeutics and vaccines, such as the COVID-19 vaccine, as well as supporting next generation therapeutics currently being developed, including lipids used for cutting-edge cancer treatments.
As the U.S. looks to expand domestic manufacturing of critical vaccines and therapeutics, Croda’s new Lamar facility, a cooperative project between the federal government and Croda, will play an important role in supporting future medicine discovery.
Bradley Cook, Vice President of Coda’s North American Operations, said:“There are rare moments that a team can contribute to such a significant betterment of humankind. The on-going collaboration with the Department of Health and Human Services and its premier biomedical countermeasure development agency, BARDA, has afforded Croda and this team the opportunity and we are extremely excited and proud.”
Construction will begin this year with the new capacity anticipated by 2025. This facility, part of an 80-acre multipurpose cGMP site, was purchased by the company in 2021, will bring up to 50 new jobs to Pennsylvania which will include engineering, administration, maintenance, operations and logistics roles. From inception, the vision of this site is to fully contribute to Croda’s sustainability goals.
